纠正:抗凝剂治疗和改变的组织因子表达有助于预防实验性胎盘和脑疟疾
PLoS pathogens
|October 24, 2025
概括
这项研究纠正了上一篇文章DOI. 修改后的DOI是10.1371/journal.ppat.1013259. 这是一个很好的方法.
科学领域:
- 科学出版业的科学出版.
- 修正条款 纠正条款 纠正条款
- 数字对象标识符 (DOI) 是一个数字对象标识符.
背景情况:
- 之前的出版物需要修正.
- 数字对象标识符 (DOI) 是不正确的.
研究的目的:
- 为了提供正确的DOI的文章.
- 确保科学出版物的准确引用和检索.
主要方法:
- 识别错误的DOI. 这是一个错误的DOI.
- 通过出版商的系统验证正确的DOI.
主要成果:
- 已经确定了错误的DOI.
- 现在已经提供了正确的DOI,10.1371/journal.ppat.1013259.
结论:
- 准确的DOI对于科学文献至关重要.
- 这种纠正确保了正确的引用和对研究的访问.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


